Manufacturing

The company is planning on adding up to 1.5 million sq. ft. of cGMP distribution space for COVID-19 shipments.

Oxford Biomedica, has signed a collaboration agreement with the not-for-profit organization, the Vaccines Manufacturing and Innovation Centre, to provide the UK with its first strategic vaccine development and advanced manufacturing capability.

The candidates will be used by the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

The companies have entered into a development and manufacturing agreement for Anthos Therapeutics’ abelacimab for treating thrombotic disorders.

Catalent will use its GPEx cell line development technology to create a cell line expressing the recombinant VLP at its Madison, WI facility.

The investment will increase production lines for bulk drug substance and will add a fill/finish production line to the site.

Siemens and Exyte partner for fast-track construction of modular, automated, digitalized biopharmaceutical facilities.

SiO2 Materials Science has received $143 million from the US government to accelerate capacity scale-up of its advanced primary packaging platform.

The VIA Capsule from Cytiva is a liquid nitrogen-free cryogenic shipment system designed to transport cell therapies.

The center will offer expertise in fill-finish optimization and analytical testing.

Achieving herd immunity will require testing, data, a vaccine, and public support.

Advances in intelligent technologies for pharmaceutical packaging improve online productivity, authenticate product, and boost patient adherence.

Consider how to assess risks and understand possible sources of disinfectant residues in pharmaceutical manufacturing.

Advanced analytics streamlines continuous manufacturing by providing improved insights to data.

The global COVID-19 pandemic has highlighted the need for the pharmaceutical industry to strengthen its supply chain.

The companies have entered into a manufacturing agreement for the fill finish supply of lenzilumab for the potential treatment of COVID-19.

The acquisition gives Novovax an annual operating capacity of more that one billion doses of COVID-19 vaccine antigen.

The right approach to biological safety cabinets, and collaboration between engineers and those who will operate the equipment, is crucial to preventing cell-culture contamination.

Developer and supplier of film coating systems and excipients, Colorcon, has launched a new platform of on-dose technologies and detection services for the authentication of medications.

Merck will acquire Themis Bioscience and collaborate with IAVI and Ridgeback Bio on COVID-19 vaccines and therapies.

The new facility in County Mayo includes an ISO class 7 cleanroom for the manufacturing of single-use systems.

CordenPharma and Moderna extended a strategic manufacturing services agreement for the supply of lipid excipients to be used in Moderna’s vaccine against SARS-CoV-2.

Advent manufactured the vaccine doses for the Phase 2/3 clinical trial.

The 60,000-ft2 facility will work in conjunction with the company’s Kakegawa, Japan, clinical supply facility to serve local and global biotech and pharmaceutical companies.

The companies have formed a collaboration to develop a novel human recombinant protein as a therapeutic candidate against COVID-19.